Interferon plus amantadine has no superiority to IFN monotherapy in naive patients with chronic hepatitis C

Basit Öğe Kaydı
dc.contributor.authorVardar, R
dc.contributor.authorKarasu, Z
dc.contributor.authorGunsar, F
dc.contributor.authorAkarca, U
dc.contributor.authorErsoz, G
dc.contributor.authorBatur, Y
dc.date.accessioned2019-10-27T18:20:40Z
dc.date.available2019-10-27T18:20:40Z
dc.date.issued2001
dc.departmentEge Üniversitesien_US
dc.identifier.endpage178en_US
dc.identifier.issn0168-8278
dc.identifier.startpage178en_US
dc.identifier.urihttps://hdl.handle.net/11454/35818
dc.identifier.volume34en_US
dc.identifier.wosWOS:000169243400653en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleInterferon plus amantadine has no superiority to IFN monotherapy in naive patients with chronic hepatitis Cen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu